- Home
- CHNR vs KTTA Comparison
CHNR vs KTTA Comparison
Compare CHNR & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- KTTA
- Stock Information
- Founded
- CHNR N/A
- KTTA 2020
- Country
- CHNR China
- KTTA United States
- Employees
- CHNR N/A
- KTTA N/A
- Industry
- CHNR Precious Metals
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- KTTA Health Care
- Exchange
- CHNR Nasdaq
- KTTA Nasdaq
- Market Cap
- CHNR 4.7M
- KTTA 5.3M
- IPO Year
- CHNR 1995
- KTTA 2021
- Fundamental
- Price
- CHNR $3.32
- KTTA $0.33
- Analyst Decision
- CHNR
- KTTA
- Analyst Count
- CHNR 0
- KTTA 0
- Target Price
- CHNR N/A
- KTTA N/A
- AVG Volume (30 Days)
- CHNR 18.6K
- KTTA 508.7K
- Earning Date
- CHNR 12-12-2025
- KTTA 11-13-2025
- Dividend Yield
- CHNR N/A
- KTTA N/A
- EPS Growth
- CHNR N/A
- KTTA N/A
- EPS
- CHNR N/A
- KTTA N/A
- Revenue
- CHNR N/A
- KTTA N/A
- Revenue This Year
- CHNR N/A
- KTTA N/A
- Revenue Next Year
- CHNR N/A
- KTTA N/A
- P/E Ratio
- CHNR N/A
- KTTA N/A
- Revenue Growth
- CHNR N/A
- KTTA N/A
- 52 Week Low
- CHNR $3.16
- KTTA $0.28
- 52 Week High
- CHNR $8.20
- KTTA $3.85
- Technical
- Relative Strength Index (RSI)
- CHNR 25.25
- KTTA 24.18
- Support Level
- CHNR $3.21
- KTTA $0.28
- Resistance Level
- CHNR $3.84
- KTTA $0.75
- Average True Range (ATR)
- CHNR 0.25
- KTTA 0.08
- MACD
- CHNR -0.09
- KTTA -0.05
- Stochastic Oscillator
- CHNR 10.00
- KTTA 11.98
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).